LabCorp (LH) has consistently shown strong performance, topping Q1 and Q2 earnings and raising EPS views for 2022 and 2024 but experienced slight underperformance in revenue estimates. They completed the
Fortrea spin-off and made a series of business acquisitions, which includes selective assets of
BioReference Health's Diagnostics business and
Invitae. They launched
Global Trial Connect aiding clinical trials and exhibited commitment to advancing their diagnostic capabilities. However, insider sales from EVPs and CMOs suggest some reservations amidst the assets buyout. LabCorp's collaboration with
Hawthorne Effect to enhance local clinical trials resonated positively. They lead on value for long-term investors with remarkable five-year returns and upcoming dividend payout. However, their three-year earnings growth isn't aligning with such returns. The
Mpox testing kit received the FDA's EUA approval, and they introduced a weight loss management portfolio. Predictions from analysts show a 'Moderate Buy' suggestion while stressing on the importance of a review of the company's plans.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Sat, 29 Jun 2024 13:02:04 GMT -
Rating 4
- Innovation -3
- Information 7
- Rumor 2
